ghrelin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
== Factors influencing bioavailability == The absolute bioavailability of a drug, when administered by an extravascular route, is usually less than one (i.e., F< 100%). Various physiological factors reduce the availability of drugs prior to their entry into the systemic circulation. Whether a drug is taken with or without food will also affect absorption, other drugs taken concurrently may alter absorption and first-pass metabolism, intestinal motility alters the dissolution of the drug and may affect the degree of chemical degradation of the drug by intestinal microflora. Disease states affecting liver metabolism or gastrointestinal function will also have an effect. Other factors may include, but are not limited to:
Aside from its acute effects, BRD-6929 was not well-tolerated and compromised health with chronic administration for 10 days in rodents, whereas no health compromise was observed with chronic administration of vorinostat. On the other hand, in another study, BRD-6929 produced longevity-enhancing effects in rodents in multiple organ systems, including the kidney, brain, and heart. BRD-6929 has been found to rescue chlorpyrifos-induced social deficits in zebrafish similarly to butyric acid (butyrate).
=== October === 1 October – The Government confirms it will not sell its shares in the electrical generation sector but will instead increase capital investments and the enforcement powers of the Electricity Authority. 2 October: The Police and Serious Fraud Office (SFO) end their criminal investigation into alleged electoral misconduct at the Manurewa Marae during the 2023 New Zealand general election, citing insufficient evidence of corruption. Māori activist group Toitū Te Tiriti, led by Eru Kapa-Kingi, severs its formal relationship with Te Pāti Māori, citing leadership differences and a desire for independence. Three new measles cases are reported in the Northland Region, bringing the total number of cases nationwide to ten. 4 October — The Presbyterian Church of Aotearoa New Zealand issues its second apology to survivors of historical abuse in Auckland. 6 October: Mike Davidson is elected as a list MP for the Green Party following the resignation of Benjamin Doyle. The New Zealand government agrees to pay Samoa 10 million tala ($3.6 million) in compensation for the sinking of HMNZS Manawanui in 2024. 7 October — ASB Bank agrees to pay NZ$135.6 million to settle a lawsuit relating to alleged breaches of the Credit Contracts and Consumer Finance Act. ANZ Bank New Zealand declines to settle the lawsuit with plaintiffs. 8 October — Over 100 pro-Palestinian protesters attempt to disrupt the New Zealand Aerospace Summit 2025 at Christchurch's Te Pae Convention Centre. Police arrest 22 protesters.
=== Chiral crown ether === Chiral crown stationary phases consist Crown ethers, immobilized or bonded to the support particles, are polyethers with a macrocyclic structure that can create host-guest complexes with alkali, earth-alkali metal ions, and ammonium cations. The skeleton of the cyclic structure is composed of oxygen and methylene groups arranged alternately. The electron-donating ether oxygens are positioned within the inner wall of the crown cavity, and are encircled by methylene groups in a collar-like arrangement. The chiral recognition is based on two distinct diastereomeric inclusion complexes that can be generated. The primary interactions facilitating complexation involve hydrogen bonds, formed between the three amine hydrogens and the oxygens of the macrocyclic ether, arranged in a tripod configuration. Additionally, ionic interactions, dipole-dipole interactions, or hydrogen bonds can occur between the carbocyclic groups and polar groups of the analytes, providing further support for the complexes.
==== Switzerland ==== The aim of the Radon Action Plan 2012-2020 in Switzerland was to incorporate the new international recommendations into the Swiss strategy for protection against radon and thus reduce the number of lung cancer cases attributable to radon in buildings. On 1 January 2018, the limit value of 1000 Bq/m3 was replaced by a reference value of 300 becquerels per cubic meter (Bq/m3) for the radon gas concentration averaged over a year in "rooms in which people regularly spend several hours a day". Subsequently, on May 11, 2020, the Federal Office of Public Health FOPH issued the Radon Action Plan 2021-2030. The provisions on radon protection are primarily laid down in the Radiation Protection Ordinance (RPO).
Sources: en.wikipedia.org
The class of endorphins consists of three endogenous opioid peptides: α-Endorphin, β-endorphin, and γ-endorphin. The endorphins are all synthesized from the precursor protein, proopiomelanocortin (POMC), and all contain a met-enkephalin motif at their N-terminus: Tyr-Gly-Gly-Phe-Met. α-endorphin and γ-endorphin result from proteolytic cleavage of β-endorphin between the Thr(16)-Leu(17) residues and Leu(17)-Phe(18) respectively. α-endorphin has the shortest sequence, and β-endorphin has the longest sequence. α-Endorphin and γ-endorphin are primarily found in the anterior and intermediate pituitary. While β-endorphin is studied for its opioid activity, α-endorphin and γ-endorphin both lack affinity for opiate receptors and thus do not affect the body in the same way that β-endorphin does. Some studies have characterized α-endorphin activity as similar to that of psychostimulants and γ-endorphin activity to that of neuroleptics separately.
=== Mood and stress === The involvement of KOR in stress, as well as in consequences of chronic stress such as depression, anxiety, anhedonia, and modulating drug-seeking behavior, has been widely investigated. KOR is postulated to play an important and varied role in regulating various affective state and stress responses in humans through multiple complex processes. There have been numerous studies implicating KOR in pathology of various psychiatric disorders. One of the main premises for this investigation comes from the receptor activation causing cellular hyperpolarization and, in neurons, decreased neurotransmitter release through a reduction in calcium and increase in potassium conductance. Through these mechanisms, KORs are thought to regulate the release of many signaling molecules including: γ-aminobutyric acid (GABA), glutamate, serotonin, dopamine, norepinephrine. Results on exact influence on neuronal activity and neurotransmitter release vary in vivo. KOR activation elicits immediate hyperpolarization of dopamine neurons (in 1–2 min), followed by decreased dopamine release (5–10 min) and secondary effects on serotonin and glutamate (10–30 min).
60) set an upper limit of 5,000 per gram, and rejected any batch of vaccine found to contain the causative organisms of erysipelas or wound infections. Unfortunately glycerolated vaccine lost its potency quickly at ambient temperatures which restricted its use in tropical climates. However, it remained in use into the 1970s when a satisfactory cold chain was available. Animals continued to be widely used by vaccine producers during the smallpox eradication campaign. A WHO survey of 59 producers, some of whom used more than one source of vaccine, found that 39 used calves, 12 used sheep and 6 used water buffalo, whilst only 3 made vaccine in cell culture and 3 in embryonated hens' eggs. English vaccine was occasionally made in sheep during World War I but from 1946 only sheep were used. In the late 1940s and early 1950s, Leslie Collier, an English microbiologist working at the Lister Institute of Preventive Medicine, developed a method for producing a heat-stable freeze-dried vaccine in powdered form. Collier added 0.5% phenol to the vaccine to reduce the number of bacterial contaminants but the key stage was to add 5% peptone to the liquid vaccine before it was dispensed into ampoules. This protected the virus during the freeze drying process. After drying, the ampoules were sealed under nitrogen. Like other vaccines, once reconstituted it became ineffective after 1–2 days at ambient temperatures. However, the dried vaccine was 100% effective when reconstituted after 6 months storage at 37 °C (99 °F) allowing it to be transported to, and stored in, remote tropical areas.
In 1973 "by Direction of the President, Major General Liu Wan-Tsai, Chinese Air Force, [was] awarded the Legion of Merit (Degree of Officer) for exceptionally meritorious service as Air Attache, Embassy of the Republic of China, Washington, D.C., from 4 April 1969 to 27 July 1972." In 1996, Lieutenant General Roméo Dallaire of the Canadian Army was made an Officer of the Legion for his role as Commander of the United Nations peacekeeping force in Rwanda during the civil war and subsequent genocide. On 18 December 1980 Major General Shlomo Inbar, Israel Army, was made an Officer of the Legion of Merit for his exceptionally meritorious conduct in the outstanding performance of duties as Defense and Armed Forces Attache, Embassy of Israel to the United States of America, from July 1977 to August 1980. In 2000, Lieutenant General Danfer G. Suarez was made an Officer of the Legion "Exceptionally meritorious conduct in the performance of outstanding services as the Peruvian Air Attache from 1997 to 1998. In 2006, Lieutenant General Nick Houghton, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq." In 2007, Lieutenant General Sir Robert Fry, Royal Marines, "in recognition of gallant and distinguished service during coalition operations in Iraq. Lieutenant General Tariq Khan became the fourth Pakistani officer to receive the award for meritorious services as a liaison officer at CENTCOM during Operations Enduring Freedom (December 9, 2007).
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。